AbstractBySubCategory

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009-014907-29). Beatrice M. Seddon

10500

A randomized phase Ib/II study evaluating the safety and efficacy of olaratumab (IMC-3G3), a human anti-platelet-derived growth factor α (PDGFRα) monoclonal antibody, with or without doxorubicin (Dox), in advanced soft tissue sarcoma (STS). William D. Tap

10501

A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). George D. Demetri

10503

Activity of regorafenib (RE) in leiomyosarcomas (LMS) and other types of soft-tissue sarcomas (OTS): Results of a double-blind, randomized placebo (PL) controlled phase II trial. Olivier Mir

10504

The somatic mutational landscape in soft tissue sarcoma: Early results from TCGA data. Andrew Scott Brohl

10508

Next generation sequencing of synovial sarcomas. Myrella Vlenterie

10509

Clinical application of prognostic gene expression signature in fusion gene-negative rhabdomyosarcoma: A report from the Children’s Oncology Group. Pooja Hingorani

10510

Forty years of randomized trials in advanced/metastatic soft tissue sarcoma (STS): Endpoint selection, surrogacy and quality of reporting. Alona Zer

10513

A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS). Steven Attia

10514

A phase II study of tivozanib in patients with metastatic and non-resectable soft tissue sarcomas. Mark Agulnik

10515

A phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS). Joanna Vitfell-Rasmussen

10516

Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? Myriam Weyl Ben Arush

10540

Combined sunitinib and IMRT for preoperative treatment of locally advanced soft tissue sarcoma: Results of a phase I trial of the German Interdisciplinary Sarcoma Group GISG 03. Jens Jakob

10541

Activity of crizotinib (C) in patients (pts) with clear cell sarcoma (CCSA) in EORTC phase II trial 90101 "CREATE". Patrick Schoffski

10542

High-risk soft tissue sarcoma of extremity and trunk wall: A retrospective comparison of local control in patients treated with or without radiation therapy at a single reference center. Marco Fiore

10543

Association of hematological toxicity (tox) and outcome to doxorubicin (DOX) in advanced soft tissue sarcoma (STS): A retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database. Stefan Sleijfer

10544

Metastatic soft tissue sarcoma, an analysis of systemic therapy and impact on survival. Samuel John Harris

10545

Longer term cardiac safety of aldoxorubicin. Sant P. Chawla

10546

Surrogate properties of survival endpoints in metastatic soft-tissue sarcoma: A meta-analysis. Marion Savina

10547

Cost-effectiveness analysis of preoperative versus postoperative radiotherapy in resectable extremity soft tissue sarcoma. Melody Xuan Lu Qu

10548

Epidemiology, treatment (tx) patterns and outcomes in Asian soft tissue sarcoma (STS) patients: Results from the Soft Tissue Sarcoma in the Asia Pacific Region (STAR) study. Richard Hong Hui Quek

10549

Targeted next generation sequencing in well-differentated/dedifferentiated liposarcoma (WD/DD LPS): Multiple gene amplifications but few mutations. Neeta Somaiah

10550

A retrospective analysis of patients with soft tissue sarcoma treated long-term with trabectedin. Elizabeth J. Davis

10551

Multimodal treatment of pulmonary artery sarcoma: A single center experience. Simona Secondino

10552

Metastatic dermatofibrosarcoma protuberans (DFSP) and fibrosarcomatous DFSP (FS-DFSP): Sensitivity to imatinib (IM) and gene expression profile. Silvia Stacchiotti

10553

Natural history and outcome in a large series of primary dermatofibrosarcoma protuberans (DFSP) treated at a reference institution. Andrea Pierluigi Fontana

10554

The lipogenic phenotype reprograms the epigenome in sarcomas. Warren Allen Chow

10555

Primary high-grade myxofibrosarcoma/pleomorphic malignant fibrous histiocytoma: Percent myxoid component to improve outcome prediction. Ann Yeelin Lee

10556

Postoperative morbidity and mortality in a large series of primary retroperitoneal sarcoma (RPS) treated at 8 tertiary centers: A study from the Transatlantic RPS Working Group. Dirk C Strauss

10557

Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center. Michael Wagner

10558

The benefit of adjuvant radiotherapy in high-grade retroperitoneal sarcoma: A SEER analysis. James Edward Bates

10559

A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas. Christian Frederick Meyer

10560

Imatinib mesylate (IM) activity in patients (pts) with locally advanced tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT). Philippe Alexandre Cassier

10561

Sunitinib malate in advanced alveolar soft part sarcoma (ASPS): A final update after the closure of the named use program. Nadia Hindi

10562

Phase II trial of PF-03084014 in adults with desmoid tumors/aggressive fibromatosis. Shivaani Kummar

10563

A phase I trial of the human double minute 2 (HDM2) inhibitor MK-8242 in patients (pts) with advanced solid tumors. Andrew J. Wagner

10564

Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma. Chan Kim

10565

Time to secondary resistance (TTSR) after rechallenge with trabectedin (T) in myxoid round cell liposarcoma (MRCLPS) patients. Roberta Sanfilippo

10566

Pazopanib for soft tissue sarcoma (STS) in the first- line setting with denosumab. Hiroyuki Narahara

10567

A new simple low-cost multiplexed targeted sequencing assay to detect recurrent fusion genes in sarcomas. Emilie Angot

10568

A phase 1b study with selinexor, a first in class selective inhibitor of nuclear export (SINE) in patients with advanced sarcomas: An efficacy analysis. Mrinal M. Gounder

10569

Pattern of relapse in limb/girdle low-grade liposarcoma/atypical lipomatous tumor (ALT) during guidelines-suggested follow up (FU). Raimondo Piana

10570

Primary chest wall soft tissue sarcomas: predictors of survival following surgical resection in a large population cohort. Sadiq Rehmani

10571

Local control following resection of primary retroperitoneal sarcoma with and without preoperative radiotherapy. Carol Jane Swallow

10572

Phase 2 study of gemcitabine, docetaxel, and doxorubicin in patients with advanced, unresectable, and/or metastatic sarcoma who have failed prior therapies. Andrew Eugene Hendifar

10573

Metastatic Non-Uterine Leiomyosarcoma: Prognostic factors, Overall Survival and chemotherapy outcomes. Sandra P. D'Angelo

10574

Two cases of sarcomas in the heart; one primary, one metastatic. Gul Sema Yildiran Keskin

e21510

Development of an in vivo TEM-1 PET test for clinical screening applications. Sara ES Lange

e21511

The role of AURKA in liposarcoma. Chueh-Chuan Yen

e21512

PET/CT-guided percutaneous biopsy for diagnosis of MPNST in Neufibromatosis Type 1 (NF1). Patrick Combemale

e21513

Serum troponin surveillance to predict cardiotoxicity of doxorubicin in adults with metastatic sarcoma. Samuel John Harris

e21516

C-reactive protein (CRP) and peripheral blood monocyte count (PBMC) in patients (pts) with advanced soft tissue sarcomas (ASTS) treated with trabectedin (TR): correlation with progression-free survival (PFS). Danilo Galizia

e21517

Dynamics of some biochemical markers in blood of patients with soft tissue sarcoma. Irina Aleksandrovna Goroshinskaya

e21518

Retrospective analysis of the use of paclitaxel in HIV patients with Kaposi Sarcoma (KS): Institutional experience. Adolfo B. Marantz

e21519

Kaposi sarcoma: A retrospective review. María Ángeles Vaz Salgado

e21520

Palliative intra-arterial high-dose cisplatin for inoperable sarcoma. Marcus Paulo Fernandes Amarante

e21521

Survival post relapse of soft tissue limb sarcomas: A 10-year retrospective review. Shailendra Verma

e21522

Risk factors for ifosfamide-related encephalopathy (IRE) in sarcoma (S) patients (pts). Natacha Stern

e21523

Low-dose chemotherapy with methotrexate and vinblastine for Japanese patients with desmoid tumors: Relationship to CTNNB1 mutational status. Yoshihiro Nishida

e21524

Soft tissue sarcomas in the general and referral population: The University of Maryland Medical Center experience. Michael Nathenson

e21525

Treatment of HIV-associated Kaposi's sarcoma with aldoxorubicin. Christopher Parsons

e21526

Risk factors of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment. Kenji Nakano

e21527

Evaluation of a predictive staging model for Kaposi sarcoma in Uganda. Fred Machyo Okuku

e21528

Sarcoma risk after laparoscopic surgery: A retrospective analysis. Wolfgang Nemec

e21529

Radiation associated angiosarcoma of the the breast treated with trimodality of surgery, radiation, and paclitaxel-based chemotherapy. Halle Elizabeth Foss

e21532

Sarcomas of the digestive tract (excluding GISTs) (SDT): A study of 63 patients from the French Sarcoma Group (GSF) database. Clemence Toullec

e21533

Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). Patrick Schöffski

LBA10502

A randomized phase II/III study, comparing perioperative adriamycin plus ifosfamide versus gemcitabine plus docetaxel for operable high grade soft tissue sarcomas in extremity or trunk: JCOG1306. Kazuhiro Tanaka

TPS10575

EPAZ: A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma of the Working Group Medical Oncology (AIO) and German Interdisciplinary Sarcoma Group (GISG). Viktor Gruenwald

TPS10576

A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma. Sant P. Chawla

TPS10577

SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. Melissa Amber Burgess

TPS10578